Gan & Lee Pharmaceuticals.
603087
Rang in aandelen
#3007
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aandeelprijs
$10.03
Marktkapitalisatie
$5.99B
Verandering (1 dag)
-3.71%
Verandering (1 jaar)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Categorie
Healthcare
Koersgeschiedenis voor Gan & Lee Pharmaceuticals. (603087)
Hoogste slotkoers: $10.28 op 2026-10-01
Laagste slotkoers: $9.67 op 2020-06-01
Laagste slotkoers: $9.67 op 2020-06-01
Koersgeschiedenis van Gan & Lee Pharmaceuticals. van 2020 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 0.50% |
| 2025 | 49.04% |
| 2024 | -17.59% |
| 2023 | 56.66% |
| 2022 | -56.78% |
| 2021 | -39.34% |
| 2020 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $441.33 | -16.26% |
US
|
|
| $197.82 | -45.30% |
FR
|
|
| $170.48 | 12.48% |
JP
|
|
| $198.36 | 34.13% |
US
|
|
| $70.09 | -8.42% |
CH
|
